Form 8-K

8-K — Elicio Therapeutics, Inc.

Accession: 0001601485-26-000050

Filed: 2026-06-24

Period: 2026-06-24

CIK: 0001601485

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Documents

8-K — angn-20260624.htm (Primary)

EX-99.1 (kolmpdacdeck.htm)

GRAPHIC (kolmpdacdeck001.jpg)

GRAPHIC (kolmpdacdeck002.jpg)

GRAPHIC (kolmpdacdeck003.jpg)

GRAPHIC (kolmpdacdeck004.jpg)

GRAPHIC (kolmpdacdeck005.jpg)

GRAPHIC (kolmpdacdeck006.jpg)

GRAPHIC (kolmpdacdeck007.jpg)

GRAPHIC (kolmpdacdeck008.jpg)

GRAPHIC (kolmpdacdeck009.jpg)

GRAPHIC (kolmpdacdeck010.jpg)

GRAPHIC (kolmpdacdeck011.jpg)

GRAPHIC (kolmpdacdeck012.jpg)

GRAPHIC (kolmpdacdeck013.jpg)

GRAPHIC (kolmpdacdeck014.jpg)

GRAPHIC (kolmpdacdeck015.jpg)

GRAPHIC (kolmpdacdeck016.jpg)

GRAPHIC (kolmpdacdeck017.jpg)

GRAPHIC (kolmpdacdeck018.jpg)

GRAPHIC (kolmpdacdeck019.jpg)

GRAPHIC (kolmpdacdeck020.jpg)

GRAPHIC (kolmpdacdeck021.jpg)

GRAPHIC (kolmpdacdeck022.jpg)

GRAPHIC (kolmpdacdeck023.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: angn-20260624.htm · Sequence: 1

angn-20260624

0001601485false06/24/2026Nasdaq☒00016014852026-06-242026-06-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 24, 2026

Elicio Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39990

11-3430072

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

451 D Street, 5th Floor

Boston, Massachusetts 02210

(Address of principal executive offices, including zip code)

(857) 209-0050

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

(Title of each class) (Trading Symbol) (Name of exchange on which registered)

Common Stock, $0.01 par value per share ELTX

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 24, 2026, Elicio Therapeutics, Inc. (the “Company”) hosted a virtual key opinion leader event highlighting the path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma featuring key opinion leaders, Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology Program, and Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami. The presentation is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Exhibit

Description

99.1

Company Presentation dated June 24, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Elicio Therapeutics, Inc.

By: /s/ ROBERT CONNELLY

Date: June 24, 2026

Robert Connelly

President and Chief Executive Officer

(Principal Executive Officer)

EX-99.1

Filename: kolmpdacdeck.htm · Sequence: 2

kolmpdacdeck

AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Metastatic mKRAS PDAC JUNE 24, 2026

Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness or the information contained in or incorporated by reference into the Presentation. We will not have any liability for any representations or warranties, express or implied, contained in, or omissions from, the Presentation. The data contained herein is derived from various internal and external sources. We do not assume any obligation to provide the recipient with access to any additional information or to update the information in the Presentation. Industry and Market Data The Presentation contains certain market data and other statistical information such as the size, growth and share of the industries and the market segments we operate in, which are based on information from independent industry organizations and other third-party sources, industry publications, surveys and forecasts. Such data may include projections based upon a number of assumptions. Neither we nor any third parties that provide information to us guarantee the accuracy, completeness, timeliness or availability of any information. We are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or the results obtained from the use of such content. We do not give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use, and we expressly disclaim any responsibility or liability for direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including lost income or profits and opportunity costs) in connection with the use of the information herein. The industry may not grow at the rate projected by market data, or at all. Failure of our industries to grow at the projected rate may have a material adverse effect on our business and the market price of our securities. In addition, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based upon these assumptions. You should not place undue reliance on these forward-looking statements Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. Statements in this presentation that are not purely historical are forward- looking statements. Such forward-looking statements include, among other things, statements regarding our planned clinical programs, including the timing and outcome of planned clinical trials, including the planned Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition in metastatic PDAC; the potential validation of the combination in a Phase 1 study; the potential of our product candidates, including the potential of ELI-002 7P; the potential for the Phase 1 study to provide a rapid development pathway for ELI-002 7P; the potential for the Phase 1 study to inform future metastatic PDAC and Phase 3 adjuvant PDAC development; the potential for ELI-002-induced immune priming to synergize with other therapies to enable tumor eradication; the potential for future expansion of ELI-002 to other mPDAC combinations or indications, including in mKRAS positive lung cancer and other mKRAS positive cancers; the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, our plans to develop and commercialize our product candidates, including ELI-002 7P; the timing of initiation of our planned clinical trials; the timing of the availability of data from our planned clinical trials; the timing of any planned investigational new drug application or new drug application; our plans to research, develop and commercialize our current and future product candidates; and our estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in our Annual Report on Form 10-K filed with the SEC on March 12, 2026, under the heading “Risk Factors”, and any subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this Presentation are based on information available to us as of the date of this Presentation. We do not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this Presentation, except to the extent required by law. 2 | Elicio Therapeutics

SpeakerAgenda Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical OfficerIntroduction01 Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology ProgramReview of Historical mPDAC Studies02 Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of MiamimPDAC Complete Responses03 Christopher Haqq, M.D., Ph.D.Translational Medicine Data04 Christopher Haqq, M.D., Ph.D.Phase 1 Strategy05 Christopher Haqq, M.D., Ph.D.Conclusion 06 Zev Wainberg, M.D., Peter Hosein, M.D., and Christopher Haqq, M.D., Ph.D.Discussion and QnA07 3 Peter Hosein, M.D. Zev Wainberg, M.D. Chris Haqq, M.D., Ph.D. | Elicio Therapeutics

Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer

Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment, Subsequent Therapy in metastatic PDAC 5 Hypothesis: ELI-002 7P primes mKRAS-specific immunity to enhance responsiveness to subsequent treatment Elicio believes these observations provide preliminary clinical support for evaluating ELI-002 7P in combination with checkpoint inhibition in metastatic mKRAS pancreatic cancer. • 100% confirmed complete radiographic and metabolic responses in three patients who received ELI-002 7P treatment and received subsequent nivolumab-based therapy • Subsequent therapy included chemotherapy, checkpoint inhibition, and radiation • Prospective study needed to confirm these observations Promising preliminary responses • Complete responses are rare in metastatic PDAC, particularly in MSS/MMR-proficient disease where checkpoint inhibitors have shown limited activity • These observations are therefore notable relative to historical experience Supports differentiated therapeutic potential | Elicio Therapeutics MSS: Micro-satellite stable; MMR: Mismatch Repair

Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology Program

Complete Responses Remain Rare in Metastatic Pancreatic Cancer Across Therapeutic Modalities 7 | Elicio Therapeutics Published studies evaluating chemotherapy, checkpoint inhibitors, and targeted therapies generally report complete response rates ranging from 0–8% CR signalPopulationRegimen / Study 0.6% (1 / 171) 1First Line (1L) mPDACFOLFIRINOX 0% (0 / 31) 2First Line (1L) mPDACNivo + mFOLFIRINOX 2.5% (1 / 40) 3First Line (1L) RAS-mutant mPDACDaraxonrasib + GnP 8% (2 / 24) 4First Line (1L) stage IV mPDACnP + Cisplatin + Gemcitabine [1] Conroy NEJM 2011; [2] Morizane BJC Rep 2024; [3] Revolution Medicines April 21 2026 PR; [4] Jameson JAMA Oncol 2020 GnP: Gemcitabine Nab-paclitaxel Multiple complete responses remain uncommon even among the most active regimens evaluated in metastatic PDAC.

Immunotherapy with Chemotherapy or Radiation Has Not Been Effective 8 | Elicio Therapeutics Historical rates of complete response: 2-6% for Nivo + GnP, 0% for Nivo + SBRT CR SignalPopulationRegimen / Study 2% (1 / 50) 1First Line (1L) mPDACNivo + GnP (PRINCE) 3% (1 / 34) 2First Line (1L) mPDACNivo + GnP 0% (0 / 41) 3Second Line (2L) mPDACNivo + SBRT 0% (0 / 16) 4Second Line (2L) mPDACDurva + SBRT [1] Wainberg, Clinical Cancer Research. 2020; [2] Padron, Nature Medicine. 2022; CR was not confirmed [3] Chen, J Clinical Oncology. 2022; [4] Xie, Clinical Cancer Research. 2020 GnP: Gemcitabine Nab-paclitaxel; SBRT: Stereotactic Body Radiation Therapy; CR: Complete Response Multiple complete responses remain uncommon with immunotherapy combinations.

Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami

10 Three patients who recurred following ELI-002 7P treatment subsequently achieved complete radiographic response, complete metabolic response, and biomarker normalization after nivolumab-based therapy These observations provide preliminary clinical support for evaluating ELI-002 7P in combination with checkpoint inhibition in non-liver metastatic mKRAS pancreatic cancer. 3 / 3 Patients (100%) Achieved Complete Responses (CR + CMR) All 3 Patients Were MSS / MMR-Proficient Persistence of mKRAS- specific T cells observed post- chemo and CPI mKRAS-Specific CD4+ and CD8+ T Cell Responses 3 / 3 Patients with Antigen Spreading Observed 2 / 3 Patients with Complete Responses Maintained ≥9 Months CR: Complete Response; CMR: Complete Metabolic Response; MSS: Micro-satellite stable; MMR: Mismatch Repair; CPI: Checkpoint Inhibition Complete Responses Observed Following ELI-002 7P and Subsequent Checkpoint Inhibition

11 [1] June 21, 2026; GnP: Gemcitabine Nab-paclitaxel; CR: Complete Response; PR: Partial Response; PD: Progressive Disease; SBRT: Stereotactic Body Radiation Therapy; NED: No evidence of disease; PFS: Progression-free survival; DOR: Duration of response Current StatusDOR 1Nivo start → PR / CR Tumor mKRASPatient PD, SBRT, FOLFOX-Nivo, Ipi/Nivo, ERAS-0015 2.2 mo (8.3 mo PFS) 6.1 mo (CR)G12DPatient 1 PD, GnP-Nivo 11.6 mo (13.4 mo PFS) 1.5 mo (PR) 8.9 mo (CR) G12VPatient 2 NED 9.2 mo (ongoing) 2.5 mo (CR)G12DPatient 3 Durable complete responses observed following subsequent nivolumab-based therapy in three patients previously treated with ELI-002 7P These observations support further investigation of the relationship between ELI-002 7P treatment and subsequent clinical outcomes. Complete Responses Were Confirmed and Durable1

12 GnP: Gemcitabine Nab-paclitaxel; PFS: Progression-free survival; DOR: Duration of response; CT: Computed tomography; PET: Positron emission tomography; SUVmax: Standardized uptake value RECIST: Complete Response (CR) PERCIST: Complete Metabolic Response (CMR) Complete Radiographic, Metabolic, and Biomarker Resolution of Multifocal Para-esophageal and Mesenteric Nodes 0 10 20 30 40 50 60 Weeks from start of ELI-002 7P CA 19 -9 (U /m L) ELI-002 7P GnP Nivolumab Radiation Week 18: SUVmax 9.7 Week 45: SUVmax background Patient 1: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 1: PET / CT Week 18 PET / CT Week 45 PET / CT Para-esophageal and mesenteric nodes DOR: 2.2 months PFS: 8.3 months Patient 1: Complete Response Following ELI-002 7P and Subsequent Nivolumab

13 Complete Radiographic, Metabolic, and Biomarker Resolution of Gastro-hepatic Ligament Nodes Week 28: SUVmax 8.0 Week 69: SUVmax background Patient 2: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 2: PET / CT Week 28 PET / CT Week 69 PET / CT Gastro-hepatic Ligament Node CA 19 -9 (U /m L) ELI-002 7P GnP Nivolumab Radiation RECIST: Complete Response (CR) PERCIST: Complete Metabolic Response (CMR) DOR: 11.6 months PFS: 13.4 months Patient 2: Complete Response Following ELI-002 7P and Subsequent Nivolumab GnP: Gemcitabine Nab-paclitaxel; PFS: Progression-free survival; DOR: Duration of response; CT: Computed tomography; PET: Positron emission tomography; SUVmax: Standardized uptake value

14 Complete Metabolic, and Biomarker Resolution of Mesenteric Local Recurrence CA 19 -9 (U /m L) Week 35: SUVmax 8.6 Week 48: SUVmax background Patient 3: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 3: PET / CT Week 35 PET / CT Week 48 PET / CT Mesenteric Local Recurrence 0 10 20 30 40 50 60 70 80 90 Weeks from start of ELI-002 7P ELI-002 7P GnP Nivolumab Radiation RECIST: Complete Response (CR) PERCIST: Complete Metabolic Response (CMR) DOR: 9.2 months (ongoing) Patient 3: Complete Response Following ELI-002 7P and Subsequent Nivolumab GnP: Gemcitabine Nab-paclitaxel; PFS: Progression-free survival; DOR: Duration of response; CT: Computed tomography; PET: Positron emission tomography; SUVmax: Standardized uptake value

15 MSS: Micro-satellite stable; MMR: Mismatch Repair Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment and Subsequent Therapy in metastatic PDAC Warranting Further Evaluation Complete responses following ELI-002 7P treatment and subsequent nivolumab-based therapy warrant further prospective evaluation These findings support prospective evaluation of ELI-002 7P in combination with checkpoint inhibition in metastatic mKRAS pancreatic cancer. • Three patients achieved complete radiographic, metabolic, and/or biomarker responses following nivolumab-based therapy after prior ELI-002 7P treatment • All three patients had MSS/MMR-proficient disease, a population rarely responsive to checkpoint inhibition • Two of three complete responses were maintained for ≥9 months, including one ongoing response • These observations are notable relative to historical experience in metastatic PDAC • While hypothesis-generating, the findings suggest prior ELI-002 7P treatment may influence responsiveness to subsequent therapy Executive Summary

Hypothesized Mechanism for Complete Responses Following ELI-002 7P and Subsequent Therapy 16 Observations from presented patients suggest a hypothetical mechanism for anti-tumor T cell responses and tumor modulation following ELI-002 7P treatment and subsequent nivolumab-based therapy. ELI-002 7P may prime durable mKRAS-specific immunity important for responses to subsequent therapy →ELI-002 7P Treatment1 →mKRAS-Specific T Cell Expansion2 Persistent Immune Memory3 →Subsequent Therapy (Chemo, PD-1 Inhibition and / or Radiation) →Modulation of Tumor Microenvironment Deep Tumor Responses are Rare× | Elicio Therapeutics Historical Observations: →Subsequent Therapy (Chemo, PD-1 Inhibition and / or Radiation) 4 →Modulation of Tumor Microenvironment 5 Deep Tumor Responses+

T cell Infiltration after ELI-002 7P Preceded Complete Responses 17 Observations of increased T cell tumor infiltration, and modulation of tumor PD-L1 following recurrence after ELI-002 7P CD3 CD8 PD-L1 CK (PDAC) H& E M ul tip le x IF Scale: 200 µm Patient 1 Patient 2 H&E: Hematoxylin and eosin; IF: Immunofluorescence; Patient 3 biopsy samples were not evaluable by multiplex immunofluorescence T Cells CD8 T Cells Tumor PD-L1 | Elicio Therapeutics Metastatic RelapsePrimary Tumor Post-ELI-002 7P, prior to Subsequent TherapyPre-ELI-002 7P Metastatic RelapsePrimary Tumor Post-ELI-002 7P, prior to Subsequent TherapyPre-ELI-002 7P H& E M ul tip le x IF

GnP + CPI 2 ELI-002 7PBaselineTimepoint GnP + CPI 2 ELI-002 7PBaselineTimepointGnP + CPI 2 ELI-002 7PBaselineTimepoint IF N a nd /o r G rB S FC / 1x 10 6 P B M C % IL 2+ IF Nγ + a nd /o r T N Fα + a m on g C D 8+ T c el ls IF N a nd /o r G rB S FC / 1x 10 6 P BM C mKRAS-specific T cell responses1 persisted through subsequent chemotherapy and nivolumab treatment 18 Patient 1 Patient 3Patient 2 [1] Maximum ex vivo mKRAS responses determined by IFNγ/GrB Fluorospot or ICS assay at baseline, week 10 (post ELI-002 7P priming) and final post subsequent therapy timepoints [2] Subsequent therapy included GnP, nivolumab, and SBRT; GnP: Gemcitabine Nab-paclitaxel; CPI: Checkpoint Inhibition Complete responses associate with mKRAS-specific, polyfunctional, CD4+ and CD8+ T cell responses including IFNγ, TNFα, IL2, and Granzyme B | Elicio Therapeutics

Therapy Complete Responses Associated with Personalized T Cell Responses 19 3 / 3 complete responses were associated with modulation of antigen spreading T cell responses Therapy Immunogenic Non-immunogenic % of Assayed Personalized Tumor Antigens 82 18 ELI-002 7P GnP Nivolumab Radiation These findings suggest ELI-002 7P-induced immunity may extend beyond targeted KRAS mutations and promote broader anti-tumor immune responses 0 2 4 6 8 10 Therapy 0 2 4 6 8 10 0 2 4 6 8 10 Patient 1 Patient 3Patient 2 | Elicio Therapeutics GnP: Gemcitabine Nab-paclitaxel

Metastatic PDAC Phase 1 Development Strategy 20 Plans for a staged development pathway designed to evaluate ELI-002 7P + CPI across metastatic PDAC settings | Elicio Therapeutics →Recurrent metastatic PDAC (CPI combination) Treatment Naïve metastatic PDAC (CPI and/or RASi combinations) Inform Future metastatic & Adjuvant Phase 3 Development A focused Phase 1 study has the potential to generate an early assessment of clinical activity in a setting where complete responses are rarely observed. Cohort expansion to be informed by clinical, biomarker, and immune-response data Open label, initial efficacy signals expected within 3–6 months of study startRapid Readouts: Tumor biomarker, immune response analyses may provide early evidence of biological activityBiomarker Response Early Indicator Small cohorts designed to generate actionable data with limited capital deploymentCapital Efficient: Findings may inform future metastatic combination strategies and Phase 3 designDevelopment Impact:

Planned Phase 1 Study Evaluating ELI-002 7P in Combination with Checkpoint Inhibition in 1L mPDAC 21 Building on complete response observations to identify rapid clinical insights and inform future metastatic and Phase 3 development ELIGIBILITY • Recurrent and treatment-naïve metastatic PDAC • ≥1 of 7 mKRAS alleles • Measurable disease (RECIST 1.1, PERCIST) • ECOG 0–1 STUDY REGIMEN — triplet combination SOC chemotherapy backbone Gem/Nab-paclitaxel ELI-002 7P (RP2D) Prime 6 SC doses → 8-wk rest → 4 boosters → Additional ELI-002 7P dosing until progression Checkpoint Inhibitor (Q3 Weeks) Until progression or toxicity KEY PRIMARY • ORR (CR + PR, RECIST 1.1) • CR rate • DOR • Safety KEY SECONDARY • mORR (PERCIST 1.0) • PFS, OS • Immune Responses | Elicio Therapeutics SOC: Standard of care; RP2D: Recommended Phase 2 Dose; SC: Subcutaneous; ORR: Overall response rate; CR: Complete Response; PR: Partial Response Phase 1 Study Plan: Verify signal in CPI combination setting → Expand into additional mPDAC combinations (e.g., RASi) and settings

Next Steps: Advancing Clinical Development of ELI-002 7P in Metastatic PDAC in Combination with Checkpoint Inhibition and Other Therapies 22 01 02 Finalize Study Design Initiate Phase 1 Study in mPDAC, subject to funding | Elicio Therapeutics 03 Inform future development plans in metastatic PDAC, and the adjuvant PDAC Phase 3 trial

GRAPHIC

Filename: kolmpdacdeck001.jpg · Sequence: 6

Binary file (88491 bytes)

Download kolmpdacdeck001.jpg

GRAPHIC

Filename: kolmpdacdeck002.jpg · Sequence: 7

Binary file (283950 bytes)

Download kolmpdacdeck002.jpg

GRAPHIC

Filename: kolmpdacdeck003.jpg · Sequence: 8

Binary file (119303 bytes)

Download kolmpdacdeck003.jpg

GRAPHIC

Filename: kolmpdacdeck004.jpg · Sequence: 9

Binary file (42266 bytes)

Download kolmpdacdeck004.jpg

GRAPHIC

Filename: kolmpdacdeck005.jpg · Sequence: 10

Binary file (140089 bytes)

Download kolmpdacdeck005.jpg

GRAPHIC

Filename: kolmpdacdeck006.jpg · Sequence: 11

Binary file (38577 bytes)

Download kolmpdacdeck006.jpg

GRAPHIC

Filename: kolmpdacdeck007.jpg · Sequence: 12

Binary file (116254 bytes)

Download kolmpdacdeck007.jpg

GRAPHIC

Filename: kolmpdacdeck008.jpg · Sequence: 13

Binary file (99307 bytes)

Download kolmpdacdeck008.jpg

GRAPHIC

Filename: kolmpdacdeck009.jpg · Sequence: 14

Binary file (40798 bytes)

Download kolmpdacdeck009.jpg

GRAPHIC

Filename: kolmpdacdeck010.jpg · Sequence: 15

Binary file (117573 bytes)

Download kolmpdacdeck010.jpg

GRAPHIC

Filename: kolmpdacdeck011.jpg · Sequence: 16

Binary file (107514 bytes)

Download kolmpdacdeck011.jpg

GRAPHIC

Filename: kolmpdacdeck012.jpg · Sequence: 17

Binary file (142398 bytes)

Download kolmpdacdeck012.jpg

GRAPHIC

Filename: kolmpdacdeck013.jpg · Sequence: 18

Binary file (149137 bytes)

Download kolmpdacdeck013.jpg

GRAPHIC

Filename: kolmpdacdeck014.jpg · Sequence: 19

Binary file (144717 bytes)

Download kolmpdacdeck014.jpg

GRAPHIC

Filename: kolmpdacdeck015.jpg · Sequence: 20

Binary file (124575 bytes)

Download kolmpdacdeck015.jpg

GRAPHIC

Filename: kolmpdacdeck016.jpg · Sequence: 21

Binary file (137059 bytes)

Download kolmpdacdeck016.jpg

GRAPHIC

Filename: kolmpdacdeck017.jpg · Sequence: 22

Binary file (167822 bytes)

Download kolmpdacdeck017.jpg

GRAPHIC

Filename: kolmpdacdeck018.jpg · Sequence: 23

Binary file (112117 bytes)

Download kolmpdacdeck018.jpg

GRAPHIC

Filename: kolmpdacdeck019.jpg · Sequence: 24

Binary file (123034 bytes)

Download kolmpdacdeck019.jpg

GRAPHIC

Filename: kolmpdacdeck020.jpg · Sequence: 25

Binary file (135867 bytes)

Download kolmpdacdeck020.jpg

GRAPHIC

Filename: kolmpdacdeck021.jpg · Sequence: 26

Binary file (121031 bytes)

Download kolmpdacdeck021.jpg

GRAPHIC

Filename: kolmpdacdeck022.jpg · Sequence: 27

Binary file (86409 bytes)

Download kolmpdacdeck022.jpg

GRAPHIC

Filename: kolmpdacdeck023.jpg · Sequence: 28

Binary file (105692 bytes)

Download kolmpdacdeck023.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 30

v3.26.1

Cover

Jun. 24, 2026

Cover [Abstract]

Document Type

8-K

Registrant Name

Elicio Therapeutics, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-39990

Entity Tax Identification Number

11-3430072

Entity Address, Address Line One

451 D Street, 5th Floor

Entity Address, Postal Zip Code

02210

Entity Address, State or Province

Entity Address, City or Town

Boston

City Area Code

857

Local Phone Number

209-0050

Title of 12(b) Security

Common Stock, $0.01 par value per share

Trading Symbol

ELTX

Security Exchange Name

NASDAQ

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

Central Index Key

0001601485

Amendment Flag

false

Document Period End Date

Jun. 24, 2026

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration